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Cell-type-specific splicing generates numerous alter-
natively spliced transcripts playing important roles
for organ development and homeostasis, but only a
few tissue-specific splicing factors have been identi-
fied.We found that RBM24 governs a large number of
muscle-specific splicing events that are critically
involved in cardiac and skeletal muscle development
and disease. Targeted inactivation of RBM24 in mice
disrupted cardiac development and impaired sarco-
merogenesis in striated muscles. In vitro splicing as-
says revealed that recombinant RBM24 is sufficient
to promote muscle-specific exon inclusion in nuclear
extracts of nonmuscle cells. Furthermore, we de-
monstrate that binding of RBM24 to an intronic
splicing enhancer (ISE) is essential and sufficient to
overcome repression of exon inclusion by an exonic
splicing silencer (ESS) containing PTB and hnRNP
A1/A2 binding sites. Introduction of ESS and ISE con-
verted a constitutive exon into an RMB24-dependent
alternative exon. We reason that RBM24 is a major
regulator of alternative splicing in striated muscles.
INTRODUCTION
Current estimates suggest that more than 90% of human multi-
exon genes are alternatively spliced, which allows the generation
ofdifferentmRNAvariants fromasinglegene, contributingamajor
share to overall protein diversity (Pan et al., 2008). Alternative
splicing often occurs in a cell type-specific manner and is instru-
mental for cell specification andorgan function (Chen andManley,
2009). Interferencewithalternativesplicingcan lead toseveremal-
functionsanddiseases (FaustinoandCooper, 2003). The inclusion
of cell type-specific exons generates protein segments that are
frequently enriched in posttranslational modification sites and
conserved binding motifs. Proteins containing cell type-specific
segments tend to occupy central positions in protein interaction
networks and often interact with distinct partners in the respective
cells, implyinga roleof alternative splicing inestablishingcell type-
specific interactomes (Buljan et al., 2012; Ellis et al., 2012).
Alternative splicing is catalyzed by the basic spliceosome
machinery and modulated by trans-acting splicing factors andDevecis-regulatory elements located within alternative exons and/or
flanking introns (Chen and Manley, 2009). Members of the ubiq-
uitously expressed SR and hnRNP families of proteins have been
characterized extensively and have been shown to facilitate or
inhibit splice site recognition. The outcome of splicing depends
critically on the expression levels of different splicing factors
and the arrangement/affinity of binding sites (Chen and Manley,
2009). Alternative splicing is also regulated by tissue-specific
splicing factors, whichmight allowmore specific control of splice
site selection. However, only a few tissue-specific splicing fac-
tors have been identified so far (Nilsen and Graveley, 2010).
Muscle was among the first tissues in which tissue-specific
alternative splicing was observed (Llorian and Smith, 2011),
and more than 1,000 muscle-specific alternative splicing events
have been mapped (Castle et al., 2008). Unfortunately, very lit-
tle is known about the factors and the molecular mechanisms
directing muscle-specific splicing. The majority of splicing fac-
tors are RNA-binding proteins (Chen and Manley, 2009) that
regulate splicing by binding to cis-regulatory elements via one
or more RNA-binding domains, such as RNA recognition motif
(RRM), that mediate RNA-protein interactions (Maris et al.,
2005).
RBM20 and RBM24 are RNA-binding proteins with a single
RRM domain and are preferentially expressed in striated mus-
cles (Guo et al., 2012; Xu et al., 2009), where RBM20 regulates
the alternative splicing of 31 exons from 31 genes, including titin.
Mutation of RBM20 leads to dilated cardiomyopathy in humans
and rats (Guo et al., 2012). In contrast, it is unknown whether
RBM24 is involved in muscle-specific splicing and required for
heart and skeletal muscle development, although knockdown
of RBM24 has been reported to interfere with myogenesis in
X. laevis embryos (Li et al., 2010). Furthermore, it has been
shown that RBM24 regulates the stability of myogenin mRNA
(Jin et al., 2010), and its ortholog, Sup-12, plays a role in alterna-
tive splicing of ADF/Cofilin and Egl-15 in muscle cells of
C. elegans (Kuroyanagi et al., 2007; Ohno et al., 2012).
To explore the potential role of RBM24 in muscle-specific
splicing and muscle function, we inactivated RBM24 in mice
and tested the molecular function of RBM24 in various in vitro
and in vivo splicing assays. Our results indicate that RBM24 is
crucial for embryonic cardiac development and required for at
least 68 splicing events, predominantly exon inclusions. Further-
more, we demonstrate that RBM24 is sufficient to activate mus-
cle-specific splicing in nonmuscle cells and in HeLa cell nuclear
extracts in vitro. Mutational analysis of a splicing reporter derivedlopmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Inc. 87
Figure 1. RBM24 Is Essential for Cardiac Development and Required for Sarcomerogenesis
(A and B)Whole-mount in situ hybridization to visualize the expression ofRBM24 in developing embryos. Yellow arrows indicate staining in hearts, and red arrows
indicate staining in somites (A) or myotomes (B).
(C) Real-time PCR analysis of the distribution of RBM24 transcripts in different adult mouse tissues. Data were normalized to RBM24 mRNA levels in the brain.
E11.5 RBM24 WT (RBM24+/+) and mutant (RBM24/) hearts were used as positive and negative controls, respectively. Error bars represent mean ± SD from
three independent experiments. *p < 0.05.
(D–G) Images of E14.5 wild-type and mutant embryos (D and E) and isolated hearts (F and G). The yellow arrow indicates body edema.
(H and I) H&E staining of E14.5 heart paraffin sections. The black arrow points to ventricular septum defects. The green and blue arrows indicate reduced
trabeculation and compaction, respectively. The yellow arrow marks the dilated right atrium. Scale bars, 10 mm.
(J and K) Electron microscopy analysis of E11.5 RBM24 mutant and wild-type hearts. The red arrows indicate Z-discs. Scale bars, 5 mm.
(L) Western blotting of RBM24 mutants using E11.5 and E13.5 embryonic hearts. Actin was used as loading control.
See also Figure S1 and Table S1.
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RBM24 Controls Muscle-Specific Splicingfrom the Naca gene led to identification of an exonic splicing
silencer (ESS) and intronic splicing enhancer (ISS) required for
RBM24-mediated alternative splicing.
RESULTS
RBM24 Is Essential for Cardiac Development and
Sarcomerogenesis
In a screen for tissue-specific RNAbinding proteins, we detected
a strong expression of RBM24 in the heart and somites during88 Developmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Iembryonic development (Figures 1A and 1B), consistent with a
previous study (Xu et al., 2009). RT-PCR and real-time PCR anal-
ysis using a panel of adult tissues revealed that RBM24 was also
highly enriched in adult striated muscle tissues (i.e., heart and
skeletal muscles) in both mice and humans (Figures 1C and
5A). In addition, we detected expression of RBM24 in some,
but not all, tissues containing large amounts of smooth muscle
cells, suggesting that RBM24 might be expressed in a subset
of smooth muscle cells (Figure 1C). To study the function of
RBM24, we inactivated the RBM24 gene in mice by replacingnc.
Figure 2. RBM24 Regulates Alternative
Splicing in the Heart
(A) RT-PCR analysis of RBM24-dependent splicing
in different tissues. The black arrows indicate
primer positions. The green rectangles represent
RBM24-dependent exons. Naca has two isoforms,
skNAC and aNAC, generated by alternative splicing
of exon 2. skNAC, which contains exon 2, is spe-
cifically expressed in muscle tissues, whereas
aNAC is expressed ubiquitously. m-Slc25a3 rep-
resents the muscle-specific isoform of Slc25a3.
Hprt was used as an internal control.
(B) RT-PCR analysis of RBM24-dependent
splicing in E11.5 RBM24 wild-type (+/+) and
mutant (/) hearts. Hprt was used as an internal
control. Thirty PCR cycles were used.
See also Figure S2 and Table S1.
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RBM24 Controls Muscle-Specific Splicingexon 1 with an internal ribosome entry site-reverse tetracycline
transactivator expression cassette (Figures S1A and S2B avail-
able online), resulting in a complete loss of RBM24 expression
(Figures 1C and 1L). Mutant embryos (RBM24/) died between
embryonic day (E) 12.5 and E14.5, showing multiple cardiac
malformations, including ventricular septum defects, reduced
trabeculation and compaction, and dilated atria (Figures 1D–1I;
Figure S1C). Furthermore, we observed a virtually complete
loss of sarcomeres in RBM24 mutant cardiomyocytes by elec-
tron microscopy (EM). Only very few remnants of sarcomeres
were found in mutant compared with wild-type (WT) cardiomyo-
cytes, indicating a pivotal role of RBM24 in cardiac sarcomero-
genesis and heart development (Figures 1J and 1K; Figure S1D),
which is in line with a previous study demonstrating a require-
ment of RBM24 for sarcomeric assembly and cardiac contrac-
tility in zebrafish (Poon et al., 2012).
RBM24 Regulates Alternative Splicing in the Heart
To investigate whether RBM24 is involved in the regulation of
alternative splicing, we analyzed the transcriptome of WT and
RBM24/ mutant hearts by RNA sequencing (RNA-seq) (n =
3). To avoid potential secondary changes, hearts of E11.5
embryoswere used because no discernablemorphological alter-
ations of the hearts were observed at this stage (Figure S1C).
Sixty-eight splicing events were detected, which relied on the
presence of RBM24. Forty-nine RBM24-dependent splicing
events represented single-exon inclusions, six double exon in-
clusions, sevenmutually exclusive exon inclusions, and six single
exon skippings (Figure S2A; Table S1). The degree of aberrant
splicing differed considerably between distinct transcripts (Table
S1), suggesting that individual splicing events depend, to a
different degree, on RBM24, probably because of the differential
impact of splicing repressors (see below). Because the majorityDevelopmental Cell 31, 87–9of RBM24-dependent splicing events (55
of 68) were related to exon inclusions,
our results indicate that RBM24 acts pri-
marily as a splicing activator.
Several differentially spliced transcripts
that rely on RBM24 play important roles
during cardiogenesis, sarcomere forma-
tion, postnatal skeletal muscle growth,and regeneration or are involved in the pathogenesis of hypertro-
phic and dilated cardiomyopathies or skeletal myopathies. Such
examples include Naca (Park et al., 2010), Fxr1 (Mientjes et al.,
2004; Whitman et al., 2011), Abcc9 (also known as SUR2) (van
Bon et al., 2012), Slc25a3 (Mayr et al., 2007), and Usp25 and
Usp28 (Bosch-Comas et al., 2006; Valero et al., 2001). To extend
our analysis and to validate the RNA-seq data, we subjected
seven RBM24-dependent exons from seven different disease-
relevant genes to a more detailed RT-PCR analysis. In all cases
we observed a dramatic reduction ofmuscle-specific exon inclu-
sion in RBM24mutant hearts (Figure 2B; Figures S2B and S2C).
Coro6, Slc25a3, and Usp28 transcripts showed a complete loss
of muscle-specific exon inclusion, whereas a minor inclusion of
the RBM24-dependent exon was detected for Naca, Usp25,
Fxr1, and Abcc9 in RBM24 mutant hearts (Figure 2B; Figures
S2B and S2C). Analysis of different mouse tissues revealed
that RBM24-dependent exons were specifically enriched in
cardiac and skeletal muscle tissues (Figure 2A), indicating that
cardiac and skeletal muscles share major components of the
alternative splicing machinery and generate a common set of
muscle-specific exons (Castle et al., 2008). However, some
(Naca, Coro6, Usp25, and Fxr1), but not all, RBM24-dependent
exons were also expressed in the intestine and bladder (Fig-
ure 2A), which contain large numbers of smooth muscle cells,
suggesting that these exons serve specific functions in striated
and smooth muscle cells.
Next we wanted to exclude that developmental defects of the
heart nonspecifically disrupt RBM24-dependent, muscle-spe-
cific splicing and cause aberrant mRNA processing. Therefore,
we analyzed splicing of RBM24-dependent exons in NbNblNK
mutant hearts generated by Nkx2.5-Cre-mediated deletion of
Numb/Numblike by RT-PCR analysis. NbNblNK mutants die be-
tween E14.5 and E18.5 and develop multiple cardiac defects,9, October 13, 2014 ª2014 Elsevier Inc. 89
Figure 3. RBM24 Is Required for M-Band Formation in Skeletal Muscles
(A) Schematic of the RBM24OE allele, which allows tissue-specific overexpression of RBM24-EGFP fusion protein after removal of the stop cassette with a
tissue-specific Cre recombinase. The black triangles represent loxP sites.
(B) Western blot analysis of RBM24 inRBM24Resc heart and skeletal muscles. Four types of skeletal muscle (GAS, SOL, EDL, and TA) were analyzed. RBM24Resc
mice (RBM24/, Cre+/, RBM24OE+/) are labeled in red. Control 1, RBM24+/+/Cre+/+/RBM24OE +/; control 2, RBM24+/+/Cre+//RBM24OE+/; control 3,
RBM24+//Cre+//RBM24OE+/. Actin was used as a loading control.
(C) H&E staining of paraffin sections from RBM24Resc heart and skeletal muscle (TA). Tissues from RBM24+/+, Cre+/, and RBM24OE+/ mice were used as
controls. Scale bars, 500 mm for heart sections and 10 mm for skeletal muscle sections.
(D) Electronmicroscopy analysis ofRBM24Resc heart and skeletal muscle (TA) tissues. Tissues fromRBM24+/+,Cre+/,RBM24OE+/mice were used as controls.
The red and yellow arrows indicate Z-discs and M-bands, respectively. Note the loss of M-bands in RBM24Resc skeletal muscle. Scale bars, 0.5 mm.
See also Figure S3.
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RBM24 Controls Muscle-Specific Splicingincluding ventricular septum defects and reduced compaction
(Yang et al., 2012), that also occur in RBM24mutants. No signif-
icant changes in the splicing patterns of RBM24-dependent
exons occurred in NbNblNK mutant hearts (Figure S2D), indi-
cating that defects in cardiac development do not automatically
disrupt RBM24-dependent splicing in the heart.
RBM24 Is Required for M-Band Formation and
Regulates Alternative Splicing in Skeletal Muscle
Based on the strong expression of RBM24 in skeletal muscle
(Figures 1A–1C), we reasoned that RBM24 might also regulate
alternative splicing in skeletal muscle cells. To analyze the role
of RBM24 in skeletal muscle, it was necessary to overcome
the embryonic lethality ofRBM24mutants, which wasmost likely
caused by the cardiac phenotype. Therefore, we generated the
RBM24OE allele by insertion of an RBM24-EGFP expression
cassette preceded by a floxed stop cassette into the Rosa26 lo-
cus (Figure 3A). Removal of the floxed stop cassette using the90 Developmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Imyocardial-XMLC2v-Cre strain (Breckenridge et al., 2007) re-
sulted in robust expression of RBM24-EGFP in the hearts of
XMLC2v-Cre+//RBM24OE+/ mice but not of XMLC2v-Cre+/
orRBM24OE+/mice, as indicated by western blot analysis (Fig-
ure S3A). Overexpression of RBM24-EGFP in XMLC2v-Cre+//
RBM24OE+/ hearts did not cause an apparent clinical pheno-
type or cardiac defects and did not impair fertility and survival
(data not shown).
Expression of RBM24-EGFP from the Rosa26 locus in
RBM24/ hearts rescued the cardiac phenotype (Figure 3C),
although RBM24//XMLC2v-Cre+//RBM24OE+/ mice (here-
after referred to as RBM24Resc) showed a smaller body size
compared with control animals (data not shown). As expected,
western blot analysis revealed expression of RBM24-EGFP in
the heart, but not in different skeletal muscles (gastrocnemius
[GAS], soleus [SOL], extensor digitorum longus [EDL], and tibialis
anterior [TA]) (Figure 3B), whereas expression ofRBM24 from the
endogenous locus was lacking in the heart and skeletal musclesnc.
Figure 4. RBM24 Regulates Alternative Splicing in Skeletal Muscle
Real-time PCR (A and B) and RT-PCR (C) analysis of RBM24-dependent splicing in RBM24Resc heart and skeletal muscles. RNA from four different skeletal
muscles (GAS, SOL, EDL, and TA) were used. RBM24Resc mice (RBM24/,Cre+/, RBM24OE+/) are labeled in red. Control 2, RBM24+/+/Cre+//RBM24OE+/;
control 3, RBM24+//Cre+//RBM24OE+/. Hprt was used as an internal control. Thirty PCR cycles were used. Error bars represent mean ± SD from three in-
dependent experiments. *p < 0.05. See also Figure S4.
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RBM24 Controls Muscle-Specific SplicingofRBM24Resc mice (Figure 3B). RT-PCR and real-time PCR anal-
ysis indicated that expression of RBM24-EGFP in the heart did
not only rescue the morphological phenotype but also restored
the normal splicing pattern, i.e., exon inclusion, close to WT
levels (Figures 2B and 4A–4C). We reason that the presence of
residual ‘‘nonincluded’’ exons in the hearts of RBM24Resc mice
is caused by silencing of the Rosa26 locus in a minor subpopu-
lation of RBM24/ cardiomyocytes.
Morphological examination of RBM24Resc skeletal muscles by
hematoxylin and eosin (H&E) staining of paraffin sections showed
a regular tissue structure with no signs of myofiber degeneration,
inflammation, or other pathological abnormalities. However, EM
analysis revealeda lossofM-bands in sarcomeres in skeletalmus-
clesbutnot in theheartofRBM24Rescmice (Figure3D;FigureS3B),
indicating a major role of RBM24 in the formation of the M-band.
Failure of M-band formation in skeletal muscles of RBM24Resc
mice was accompanied by a significant reduction of exon inclu-
sion (Figures 4A–4C), although the reduction was not as dramatic
as inRBM24mutant hearts (Figure2B). Interestingly, nosignificant
decrease of muscle-specific exon inclusion in skeletal muscles
was found for Abcc9 (Figures 4A–4C), suggesting that heart and
skeletal muscle cells, in some cases, employ different factors or
strategies to accomplish muscle-specific splicing.
RBM24 Acts as a Bona Fide Splicing Factor
To further analyze the ability of RBM24 to promote exon in-
clusion, we overexpressed RBM24 in HeLa cells. HeLa cells ex-Devepress pre-mRNAs of several RBM24 target genes (e.g., Naca,
Coro6, Usp25, and Usp28) (Figure 5B) but are unable to accom-
plish muscle-specific splicing of RBM24-dependent exons
occurring in human muscle tissues (Figure 5A). Interestingly,
transient transfection of HeLa cells with RBM24-FL-EGFP, but
not EGFP and RBM24DRRM-EGFP, in which the RRM domain
was deleted, led to a dramatic increase of inclusion of muscle-
specific exons of Naca and Coro6 (Figure 5B). However, no
expression of muscle-specific exons of Usp25 and Usp28 was
observed (Figure 5B), indicating that additional splicing factors
missing in HeLa cells are necessary for inclusion of these exons.
However, it cannot be excluded that the absence of exon inclu-
sion for Usp25 and Usp28 in RBM24-deficient muscle cells is
caused by secondary effects.
Additional proof that RBM24 alone, together with the core spli-
ceosome, is sufficient to mediate inclusion of muscle-specific
exons was obtained using in vitro splicing assays. We con-
structed the alternative splicing reporter (SR1-3) based on the
genomic region of mouse Naca comprising exon 1 to exon 3.
The alternatively spliced exon 2 was modified by insertion of
an EcoRV restriction site, which separates the 50part (E2-1)
from the 30 part (E2-2) (Figure 5C). Transfection of theSR1-3mini-
gene into HeLa cells revealed that the alternative exon 2 was
included only in the presence of RBM24-FL-EGFP but not in
the presence of EGFP or RBM24DRRM-EGFP (Figure 5D),
demonstrating that our splicing reporter faithfully recapitulates
splicing of the endogenous Naca gene. Importantly, the additionlopmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Inc. 91
Figure 5. RBM24 Is a Bona Fide Splicing Factor
(A) RT-PCR analysis of the distribution of RBM24-dependent exons in different human tissues. Human gene names are labeledwith the prefix h-. h-Hprtwas used
as an internal control.
(B) RT-PCR analysis of RNA splicing in HeLa cells transfected with the indicated plasmids. The expression of RBM24-FL-EGFP and RBM24DRRM-EGFP was
confirmed usingmouseRRM-specific primers that detect onlyRBM24-FL-EGFPmRNAand general primers detecting expression of both transfected constructs.
FL, full-length; DRRM, RRM domain-deleted.
(C) Schematic of the Nacaminigene-splicing reporter SR1-3 (not drawn to scale) derived from the Naca genomic locus. The construct encompasses the region
from exon 1 to exon 3. Intron 1 and exon 2 were shortened internally. Exon 1 and 3 represent constitutive exons. Exon 2 represents the muscle-specific,
alternative exon. Exon 2 in SR1-3 contains two parts, E2-1 and E2-2, that were joined using an EcoRV restriction site. The double-headed arrows indicate the
genomic regions used to generate SR1-3. The lengths (base pair) of exons and introns are indicated.
(legend continued on next page)
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RBM24 Controls Muscle-Specific Splicingof purified RBM24-His recombinant protein from E. coli (Fig-
ure 5E) to HeLa nuclear extracts primed with an RNA template
generated by in vitro transcription from the SR1-3 minigene re-
sulted in inclusion of muscle-specific exon 2 into the splicing
product in the presence of ATP (Figure 5F). In the absence of
RBM24-His, exon 1 was spliced to exon 3, but the alternative
exon 2 was not included, whereas omission of ATP prevented
splicing altogether (Figure 5F). Identical results were obtained
using commercial HeLa nuclear extracts from two different sour-
ces (HNE1 and HNE2) (Figure 5F), demonstrating the robustness
of RBM24-mediated muscle-specific splicing. Taken together,
our results suggest that RBM24 is a bona fide splicing factor,
necessary and sufficient for muscle-specific splicing.
An ESS Is Required and Sufficient for Repressing
Exon Inclusion
Next we wanted to answer the question why RBM24-dependent
exons are not included into mature mRNAs when RBM24 is ab-
sent, such as in HeLa cells or in the lung and liver (Figures 2A and
5A and 5B). Previous results demonstrated that members of the
hnRNP family often repress exon inclusion by binding to se-
quences within alternative exons and/or flanking introns (Witten
and Ule, 2011). Examination of exon 2 and its flanking introns
in the splicing reporter SR1-3 revealed the presence of a single
hnRNP A1/A2 and two PTB (also known as PTBP1 or hnRNP I)
binding sites (Chen et al., 2012) in E2-1 but not in E2-2 and in
the upstream intron (Figure 6A). We also detected one PTB site
46 base pairs (bp) downstream of E2-2, which is unlikely to
contribute to splicing repression because PTB binding sites
downstream of alternative exons usually promote exon inclusion
(Llorian et al., 2010). To functionally characterize the putative
ESS within E2-1, which might suppress inclusion of RBM24-
dependent exons, we first mutated hnRNP A1/A2 and the first
and the second PTB binding sites (Figure 6A). Interestingly, mu-
tation of hnRNP A1/A2 (SR1-3/Mut5) or the second PTB (SR1-3/
Mut6), but not the first PTB (SR1-3/Mut4) binding site, resulted in
partial release of exon 2 repression (Figure 6B), suggesting that
hnRNP A1/A2, the second PTB, and additional unknown
repressor binding sites repress exon 2 inclusion. To identify the
fragment containing the unknown repressor binding sites, we
deleted parts of the 30 end of E2-1 in SR1-3/Del1 and SR1-3/
Del2 (Figure 6A). Interestingly, exon suppression in HeLa cells
was lost in both constructs, resulting in the inclusion of mus-
cle-specific exon 2, although the PTB and hnRNP A1/A2 binding
sites were still present in SR1-3/Del1 (Figure 6B). To further
define the 30 border of ESS in the 36 bp fragment deleted in
SR1-3/Del1, an additional series of deletion constructs was
generated (Figure 6A). Repression of exon 2 inclusion was lost
gradually when E2-1 was shortened in 6 bp steps from the 30
end (Figures 6A and 6C). Our results define the 30 border of
ESS 6 bp upstreamof the end of E2-1. To determine the 50 border
of ESS and to overcome the limitations of deletion approaches,
we adopted a ‘‘gain of function’’ strategy. First we generated(D) Analysis of the splicing pattern of SR1-3 after transfection into HeLa cells by
(E) Coomassie blue staining of purified RBM24-His recombinant protein.
(F) In vitro splicing using HeLa nuclear extracts. RNA probes were generated by
controls. Two different commercial sources of HeLa nuclear extracts (HNE) were
See also Figures S4 and S5.
Devethe splicing reporter SR4-6 containing a genomic region of the
Naca gene, including constitutive exons 4 and 6 and a modified
version of exon 5, which contains an EcoRV restriction site (Fig-
ure 6D). Transfection into HeLa cells followed by RT-PCR indi-
cated that SR4-6 yields a mature mRNA containing exon 4 to
exon 6, recapitulating the splicing pattern of the endogenous
Naca gene (Figure 6F). We then asked whether introduction of
the potential ESS from E2-1 of SR1-3 into SR4-6 represses the
inclusion of exon 5. To answer this question, we inserted different
fragments of E2-1 into the EcoRV site of exon 5 in SR4-6 (Figures
6D and 6E). Interestingly, the introduction of fragment R2
repressed the inclusion of exon 5 (Figure 6F). Deletion of the first
PTB site in E2-1 had nomajor effect on exon repression, whereas
truncation of fragment R2 or deletion or mutation of hnRNP A1/
A2 or the second PTB site resulted in a dramatic loss of exon
repression (Figures 6E and 6F). Taken together, our data indicate
that the hnRNPA1/A2 and PTB binding sites in E2-1 are essential
but not sufficient for repression of exon inclusion. Suppression of
exon inclusion also requires the 30 bp fragment (R1) downstream
of the second PTB site, which seems to bind unknown splicing
repressors. The complete sequence of the exonic splice silencer
(R2 fragment) is depicted in Figure S4B.
To confirm that splicing repressors are involved in the inhibi-
tion of muscle-specific exon inclusion, we knocked down PTB
and hnRNP A1/A2 in HeLa cells using small hairpin RNA (Fig-
ure S5). RT-PCR analysis revealed that knockdown of PTB and
hnRNP A1/A2 caused a significant increase of exon inclusion
for Naca, Usp28, SR1-3, and SR4-6, whereas knockdown of
hnRNP A1/A2, but not PTB, resulted in increased exon inclusion
forCoro6. Taken together, our results demonstrate that PTB and
hnRNP A1/A2 prevent inclusion of muscle-specific exons in the
absence of RBM24. The residual amount of splicing repressors
left in knockdown cells might account for the remaining exclu-
sion of muscle-specific exons. In addition, it seems likely that
the unknown repressors binding to fragment R1 will also
contribute to the repression of exon inclusion, accounting for
the partial release of exon repression in knockdown cells.
An ISE Is Required and Sufficient for
RBM24-Dependent Exon Inclusion
Based on high-throughput in vitro binding assays, it has been
suggested recently that RBM24 binds to G (A/U) GUG (Ray
et al., 2013) motifs, although it has not been validated experi-
mentally whether these motifs are required for RBM24-depen-
dent splicing. We found two clusters of GU stretches in the
Naca gene that are located in introns upstream and downstream
of exon 2 (Figure 7A). Cluster 1 is located 370 bp upstream of
exon 2 and contains four overlapping GU stretches. Cluster 2
resides 19 bp downstream of exon 2 and contains two GU
stretches separated by four nucleotides. To test the function of
these two clusters for RBM24-mediated alternative splicing,
we deleted cluster 1 (SR1-3/Del8) and cluster 2 (SR1-3/Del9)
from the SR1-3 splicing reporter (Figure 7A). Transfection intoRT-PCR using the indicated primers (black arrows).
in vitro transcription of SR1-3. Reactions without ATP were used as negative
used. RT-PCR (30 cycles) was used to analyze the splicing outcome.
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Figure 6. An ESS Is Required and Sufficient for Repression of Exon Inclusion
(A) Schematic of the E2-1 region of the splicing reporter SR1-3 and constructs generated by mutating PTB or hnRNP A1/A2 binding sites or deleting different
regions of E2-1. The dashed lines indicate the 30 end of E2-1 in the constructs. PTB and hnRNP A1/A2 binding sites are labeled in black and purple, respectively.
The positions of 50 and 30 ends of E2-1 in each construct are indicated, defining the 50 end of E2-1 in SR1-3 as position 1.
(B and C) RT-PCR analysis of RNAs isolated from HeLa cells transfected with the indicated plasmids. The black arrows label primer positions.
(D) Schematic of the splicing reporter SR4-6, which contains the region from exon 4 to exon 6 of the Naca genomic locus. Exon 5 in SR4-6 contains two parts,
E5-1 and E5-2, that were joined by the EcoRV site. The insertion site indicates the position where different exonic fragments (R1-R8, see E) from SR1-3 were
introduced.
(E) Schematic of the E2-1 region of the splicing reporter SR1-3 and different exonic fragments of E2-1 (R1-R8), which were inserted into SR4-6. The positions of 50
and 30 ends of each fragment are indicated, defining the 50 end of E2-1 in SR1-3 as position 1.
(F) RT-PCR analysis of RNAs isolated fromHeLa cells transfected with the indicated plasmids. The black arrows indicate primer positions. Thirty PCR cycles were
used in all assays, with the exception of the analysis of SR1-3/Mut4-6 mutants, for which 33 cycles were applied to obtain stronger signals.
See also Figures S4–S7 and Table S2.
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RBM24 Controls Muscle-Specific SplicingHeLa cells revealed that that cluster 2, but not cluster 1, was
required for RBM24-dependent inclusion of exon 2 (Figure 7B).
Mutation of either (SR1-3/Mut2 or SR1-3/Mut3) or both (SR1-3/
Mut1) of the GU stretches within cluster 2 abrogated exon 2 in-
clusion (Figure 7B), indicating that both GU stretches are
required for RBM24-mediated exon inclusion. Furthermore,94 Developmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Iextension of the distance between exon 2 and cluster 2 (SR1-
3/Dist1 and SR1-3/Dist2) (Figure 7A) resulted in loss of exon in-
clusion (Figure 7B), demonstrating that RBM24 requires GU
stretches to be in close proximity to exon 2.
To test whether cluster 2 is sufficient to mediate RBM24-
dependent splicing, we introduced WT and mutant cluster 2nc.
Figure 7. An ISE Is Required and Sufficient for RBM24-Dependent Exon Inclusion
(A) Schematic of exon 2 and the flanking introns of the splicing reporter SR1-3. Two clusters of GU stretches located within the flanking introns are indicated. The
cluster in the upstream intron (cluster 1) contains four overlapping GU stretches. The cluster in the downstream intron (cluster 2) contains two GU stretches
separated by four nucleotides. Schematic maps of constructs derived from SR1-3 are also shown. SR1-3/Del8 and SR1-3/Del9 contain deletions of cluster 1
and 2, respectively. SR1-3/Mut1, SR1-3/Mut2, and SR1-3/Mut3 contain mutations of both GU stretches, the first GU stretch, and the second GU stretch of
cluster 2, respectively. In SR1-3/Dist1 and SR1-3/Dist2, the distance between exon 2 and cluster 2 was increased from 19 to 40 and 60 bp, respectively.
(B) RT-PCR analysis of RNAs from HeLa cells transfected with the indicated plasmids. The black arrows indicate primer positions.
(C) Schematic of SR4-6/R2, which contains the full-length ESS (red triangle) and constructs derived from SR4-6/R2. The WT and mutant cluster 2 were inserted
19 bp downstream of exon 5 in SR4-6/R2/GU-WT and SR4-6/R2/GU-Mut, respectively. In SR4-6/R2/GU-Dist1 and SR4-6/R2/GU-Dist2, the distance between
exon 5 and cluster 2 was increased from 19 to 40 and 60 bp, respectively.
(D) RT-PCR analysis of RNAs from HeLa cells transfected with the indicated plasmids. The black arrows indicate primer positions. Thirty PCR cycles were used
for RT-PCR.
(E) Schematic of templates for in vitro transcription of biotinylated RNA probes used for pull-down assays (see F). The template contains the 30 part of E2-2 and the
50 part of the downstream intron from SR1-3. Two different mutations (T/C or G/C) were introduced into cluster 2.
(F) RNA pull-down assay of RBM24-His recombinant protein using biotinylated RNA probes containing cluster 2. RBM24-His was detected by western blot
analysis using an RBM24 antibody.
See also Figures S4–S7 and Table S2.
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RBM24 Controls Muscle-Specific Splicing19 bp downstream of exon 5 in SR4-6/R2, in which inclusion of
exon 5 is completely repressed because of insertion of ESS (Fig-
ure 6F). We found that insertion of WT (SR4-6/R2/GU-WT) but
not mutant cluster 2 (SR4-6/R2/GU-Mut) resulted in ‘‘reinclu-
sion’’ of exon 5 into the mRNA when RBM24-FL-EGFP was pre-
sent (Figures 7C and 7D), indicating that cluster 2 is sufficient to
mediate RBM24-dependent exon inclusion. Interestingly, exten-Devesion of the distance between exon 5 and cluster 2 did not affect
splicing (Figures 7C and 7D), suggesting that RBM24 does not
always need to bind in close proximity to the alternative exon.
We also investigated whether RBM24 binds directly to cluster
1 and cluster 2 using biotinylated WT and mutant RNA probes
transcribed from each clusters (Figure 7E; Figure S6A) and re-
combinant RBM24-His protein. Proteins bound to biotinylatedlopmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Inc. 95
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analyzed by western blot. We found that RBM24 efficiently binds
to both cluster 1 and cluster 2, whereas mutations (T/C or G/
C) dramatically reduced binding, indicating that RBM24 binds
directly to GU stretches in cluster 1 and 2, although binding to
cluster 1 seems to be functionally irrelevant (Figure 7F; Fig-
ure S6B). This is consistent with previous studies demonstrating
that many RNA-binding proteins bind with high affinity to
different positions in the transcriptome without an apparent
function (Ko¨nig et al., 2011). To further analyze the impact of
the localization of RBM24 binding sites on splicing, we replaced
cluster 2with cluster 1 in SR1-3, yielding SR1-3/Mut7 (Figure 7A).
Interestingly, we observed a significant increase in exon inclu-
sion after cotransfection with RBM24-EGFP (Figure 7B), sug-
gesting that cluster 1 also mediates exon inclusion, but only
when placed at the appropriate position.
Our data indicate that the balance between RBM24 and
splicing repressors is critical to achieve muscle-specific splicing
of individual alternative exons. To validate this model, we em-
ployed C2C12 muscle cells, which downregulate splicing re-
pressors and upregulate RBM24 during differentiation (Figures
S7A and S7B), concomitant with a dramatic increase in the in-
clusion of RBM24-dependent alternative exons (Figures S7C
and S7D). We reasoned that the dependence of exon inclusion
on RBM24 is reduced during C2C12 cell differentiation when
concentrations of the splicing repressors decline. In fact, stable
knockdown of RBM24 (Figures S7A and S7B) in undifferentiated
C2C12 cells (day 0) and during early differentiation (day 1 to day
2) dramatically reduced exon inclusion in the presence of high
levels of splicing repressors (Figures S7C and S7D), indicating
a strong dependence of exon inclusion on RBM24 in undifferen-
tiating skeletal muscle cells. In contrast, inclusion of muscle-
specific exons increased strongly in RBM24 knockdown cells
at later stages of differentiation (day 3 to day 5) when the con-
centration of splicing repressors was low (Figures S7C and
S7D). These results confirm the functional antagonism of the
RBM24 splicing activator and splicing repressors and suggest
that the relative concentrations to each other determine the ef-
ficiency of muscle-specific alternative exon inclusion. Interest-
ingly, RBM24 knockdown C2C12 cells failed to form myotubes
(Figure S7E), although the efficiency of exon inclusion was virtu-
ally normal at day 5 (Figures S7C and S7D), indicating that
RBM24 has additional functions during muscle cell differentia-
tion in vitro.
Bioinformatical analysis of genomic sequences located
adjacent to RBM24-dependent alternative exons identified by
RNA-seq revealed an enrichment of proximal GU stretches
downstream of alternative exons and of PTB and hnRNP A1/
A2 binding sites in regions flanking upstream intron/alternative
exon borders compared with constitutively spliced exons (Fig-
ure S4A; Table S2). Although we identified essential cis elements
required for RBM24-mediated exon inclusion, it is clear that we
did not identify all relevant parameters. For example, we found
that the 30 bp sequence (R1) downstream of the second PTB
binding site in E2-1 is required for exon repression (Figure 6),
but we did not locate known repressor binding sites therein.
The identification of additional parameters relevant for RBM24-
mediated alternative splicing will help to further decipher the
splicing code defining RBM24 targets.96 Developmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier IDISCUSSION
The identification of tissue-specific splicing factors and their
genome-wide targets is mandatory to understand the mecha-
nism of alternative splicing. So far, only a few tissue-specific
splicing factors (e.g., neuron-specific Nova and muscle-specific
RBM20) and their potential splicing targets have been described.
In this study, we characterized the tissue-specific splicing factor
RBM24 and identified 68 RBM24-dependent splicing events.
The biological function of RBM24 splicing targets such as
Naca, Fxr1, Abcc9, Slc25a3, Usp25, and Usp28, in particular
for cardiac development and sarcomerogenesis, strongly sug-
gests that dysregulated alternative splicing is responsible for
the severe malformations and lack of sarcomerogenesis in the
developing hearts of RBM24 mutants as well as for the failure
of M-band formations in adult skeletal muscles devoid of
RBM24. skNAC, the muscle-specific isoform of Naca, encodes
a transcription factor that interacts with the chromatin modifier
Smyd1/m-Bop, which is essential for cardiogenesis (Park
et al., 2010). The targeted deletion of the muscle-specific exon
2 of skNAC resulted in ventricular hypoplasia and decreased car-
diomyocyte proliferation (Park et al., 2010). Moreover, knock-
down of skNAC in zebrafish resulted in disorganized thick and
thin filaments in skeletal muscle, indicating a role of skNAC in
myofibril assembly (Li et al., 2009). The RNA binding protein
Fxr1 is also involved in sarcomere formation, as indicated by se-
vere sarcomere defects after knockout of Fxr1 in mice (Mientjes
et al., 2004).
Some RBM24-dependent targets, such as Abcc9, Slc25a3,
andUsp25, are involved in the pathogenesis of cardiac and skel-
etal muscle diseases. Abcc9, which encodes for a potassium
channel subunit, is mutated in some human dilated cardiomyop-
athies (Bienengraeber et al., 2004), and mutations of Abcc9 are
also the cause of Cantu´ syndrome, which is characterized by car-
diomegaly (van Bon et al., 2012). Mutations in the muscle-spe-
cific exon 3A of the mitochondrial phosphate carrier Slc25a3
lead to hypertrophic cardiomyopathy and muscular hypotonia
(Mayr et al., 2007). The muscle-specific isoform of Usp25 inter-
acts with the sarcomeric proteins ACTA1, FLNC, and MyBPC1,
which are critically involved in muscle differentiation and in the
pathogenesis of several myopathies (Bosch-Comas et al.,
2006; Valero et al., 2001).
Because RBM24 regulates the splicing of several develop-
ment- and disease-relevant genes, it is not possible to determine
precisely the specific contribution of each aberrantly spliced gene
to theRBM24 phenotype. However, it was interesting to note that
RBM24 regulates themuscle-specific splicing of a group of genes
that all seem to share some functional properties and participate
in the formation of sarcomeres in striated muscles. Similar obser-
vations have been made for other tissue-specific splicing factors
that tend to regulate splicing events in functionally related genes
(Guo et al., 2012;Ule et al., 2006). Interestingly, the tissue-specific
splicing of genes for related biological processes appears to
employ several different splicing factors. One of the few known
muscle-specific splicing factors, RBM20, is also involved in the
splicing of genes linked to cardiomyopathy and sarcomere
biology but shares only a single target, Tpm1, with RBM24 (Guo
et al., 2012; Table S1). It is tempting to speculate that the coordi-
nated but separately regulated control of functionally relatednc.
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tion of complex biological processes.
Our data suggest that the balance between splicing repres-
sors and activators plays a critical role in controlling splicing,
as illustrated by the diminished requirement of splicing activators
for exon inclusion when concentrations of splicing repressors
drop.We found that the absence of RBM24 in adult skeletal mus-
cle does not lead to a complete absence ofmuscle-specific exon
inclusion, as in embryonic cardiac muscle, which coincides with
a low expression level of splicing repressors such as PTB in adult
skeletal muscle (Zhang et al., 2009). In fact, downregulation of
PTB expression during myogenic differentiation has been linked
to increased exon inclusion (Boutz et al., 2007; Lin and Tarn,
2011). A differential impact of the balance between splicing acti-
vators and repressors on individual splicing events might also
explain why different RBM24 targets showed different exon in-
clusion efficiencies in RBM24mutant embryonic hearts, thereby
highlighting the role of ubiquitously expressed splicing silencers
such as hnRNPsA1/A2 and PTB in the quantitativemodulation of
tissue-specific exons (Chen and Manley, 2009). A1/A2 and PTB
act as splicing repressors when binding to exonic splicing si-
lencers (Goina et al., 2008; Izquierdo et al., 2005; Llorian et al.,
2010), whereas PTB can also act as a splicing activator when
binding to downstream introns of differentially spliced exons
(Llorian et al., 2010).
Our data demonstrate that ectopic expression of RBM24 in
HeLa cells or addition of recombinant RBM24 to HeLa nuclear
extracts results in increased inclusion of RBM24-dependent
exons, proving that RBM24 is sufficient to instruct the basic
splicing machinery for tissue-specific splicing. HeLa cell splicing
assays also helped to locate the regulatory elements bound by
RBM24 to activate the inclusion of the muscle-specific exon of
the Naca gene. A detailed mutational analysis of the Naca locus
revealed that RBM24 acts only on the downstream intron of the
alternative exon, whereas both flanking introns (upstream and
downstream) need to be removed to achieve inclusion of alterna-
tive exons in the presence of RBM24. These observations fit the
idea that splicing of the downstream intron represents the rate-
limiting step for exon inclusion (Ule et al., 2006). The binding sites
of RBM24 in the downstream intron act in concert with binding
sites for hnRNP A1/A2 and PTB within the alternative exon,
constituting an exonic splicing silencer, which adds further evi-
dence to the concept that hnRNP A1/A2 and PTB often coregu-
late target exons (Chen et al., 2012; Clower et al., 2010).
Our study identifies RBM24 as a major muscle-specific
splicing factor for cardiac and skeletal muscle development.
Several disease-relevant muscle-specific exons were regulated
by RBM24, which provides insights into the pathogenesis of car-
diomyopathies and disorders of the sarcomere. It was also
intriguing to see that the absence ofM-bands in skeletal muscles
lacking RBM24 did not have a major impact on the structure of
sarcomeres, which challenges the view that the M-band is
crucial for completion of sarcomere assembly during myofibrillo-
genesis (Agarkova et al., 2003). We identified essential cis ele-
ments required for RBM24-dependent single exon inclusion
that allowed us to convert a constitutive exon into an RBM24-
dependent alternative exon. It is clear, however, that we have
only seen the tip of the iceberg and that additional efforts are
necessary to understand RBM24-mediated double exon inclu-Devesion and mutually exclusive splicing. Future studies will reveal
howRBM24 counteracts splicing repressors to facilitate spliceo-
some assembly and disclose additional layers of regulation.
EXPERIMENTAL PROCEDURES
Animals
All animal manipulations were carried out in accordance with the guidelines for
animal experiments at the Max Planck Institute for Heart and Lung Research,
which conform to the Guide for the Care and Use of Laboratory Animals (NIH
Publication No. 85-23, revised 1996). The approval of animal experimentation
was granted by the local authorities (Regierungspra¨sidium Darmstadt, V54-
19c20/15-B2/158).
Western Blotting
Embryonic hearts and adult tissues were isolated and snap-frozen in liquid ni-
trogen, followed by protein extraction. Protein samples were loaded on 4%–
12% SDS-PAGE gradient gels (Invitrogen), separated, and transferred onto
nitrocellulose membranes. The following primary antibodies were used to
detect specific proteins: anti-RBM24 (1:1,000, catalog no. ab94567, Abcam),
anti-Pan-actin (1:2,000, catalog no. 4968, Cell Signaling Technology), anti-
PTBP1 (1:1,000, catalog no. 8776, Cell Signal), anti-hnRNP A1 (1:1,000, cata-
log no. 4296, Cell Signal), anti-hnRNP A2 (1:1,000, catalog no.9304, Cell
Signal), and anti-myogenin (catalog no. 556358, BDBiosciences). Horseradish
peroxidase (HRP)-conjugated secondary antibody was purchased fromPierce
and Thermo Scientific (goat anti–rabbit HRP, catalog 1858415) and detected
by SuperSignal West Femto detection solutions (Thermo Scientific).
RNA-Seq, RT-PCR, and Real-Time PCR
Total RNA was isolated from three WT and three mutant hearts (E11.5) and
used to prepare RNA-seq libraries after rRNA depletion according to Illumina
standard protocols (2 3 100 paired-end chemistry). RNA-seq analysis was
performed as described previously with some modifications (Ro¨sel et al.,
2011). All six samples were sequenced on one lane using a HiSeq 2000 instru-
ment (Illumina) employing 23100 paired-end chemistry. In total, 123.4 million
(wild-type: 48.5, 35.3, and 39.6) and 105.5million (mutant: 32.1, 45.4, and 28.0)
reads were obtained and aligned to the mouse genome (mm9) as well as to a
junction-sequence data set, which was constructed with Ensemble gene an-
notations (v. 64). Uniquely mapped reads (72% of sequenced reads) were
selected for coverage and junction read count assembly. RNA-seq data
were uploaded to the Sequence Read Archive at the National Center for
Biotechnology Information (accession no. SRP044097). For RT-PCR, 25–30
cycles for PCR were used, although similar exon inclusion ratios were
observed, even after 35 cycles, consistent with previous studies (Hou et al.,
2002). The identities of all PCR products were confirmed by sequencing.
Exon inclusion efficiency was calculated by dividing the amount of muscle-
specific products by the sum of all PCR products (Chen et al., 2012).
Real-time PCR was used to quantify exon inclusion efficiency for Naca and
Slc25a3. The 2-DDCt method was applied to calculate the relative expression
of RBM24-dependent exons relative to expression levels of constitutive exons
within the same gene that were not differentially spliced (Guo et al., 2012).
Splicing Assays in HeLa Cells
Transient transfection of HeLa cells was performed using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instruction. After 24 hr, total RNA
was isolated using TRIzol reagent and reverse-transcribed using a random
primer and Superscript II (Invitrogen). The primers were as follows: CC
CGGTGAAGCCACAGAAAC (SR1-3 forward), GAGTCTTGTTCCTCGAGCTC
(SR1-3 reverse), CGCAGCAGAGATCGATGAAG (SR4-6 forward), and
CTCCTCTTCTTCACTCTCCTC (SR4-6 reverse). The identities of all PCR prod-
ucts were confirmed by sequencing.
In Vitro Splicing Assays
An in vitro splicing assay was performed as described previously (Mayeda and
Krainer, 1999). HeLa cell nuclear extract was purchased from Jena Bioscience
(catalog no. PR-778) and Ipracell (catalog no. CC-01-20-50). Capped
pre-mRNA was in vitro-transcribed using the TranscriptAid T7 high-yieldlopmental Cell 31, 87–99, October 13, 2014 ª2014 Elsevier Inc. 97
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RBM24 Controls Muscle-Specific Splicingtranscription kit (catalog no. K0441, Thermo Scientific) and the SR1-3 splicing
reporter as a template. RT-PCR was performed to analyze the inclusion effi-
ciency of alternative exons. The identities of all PCR products were confirmed
by sequencing.
Statistics
Two-tailed Student’s t tests were used to determine the statistical significance
of differences between samples. p < 0.05 was considered significant.
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